The Association between Choroidal Thickness Variations and Response to Intravitreal Bevacizumab in Central Serous Chorioretinopathy.
10.3341/kjo.2015.29.3.160
- Author:
Dong Yoon KIM
1
;
Soo Geun JOE
;
Sung Jae YANG
;
Joo Yong LEE
;
June Gone KIM
;
Young Hee YOON
Author Information
1. Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. yhyoon@amc.seoul.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Central serous chorioretinopathy;
Enhanced depth image-optical coherence tomography;
Subfoveal choroidal thickness
- MeSH:
Adult;
Angiogenesis Inhibitors/administration & dosage/*therapeutic use;
Bevacizumab/administration & dosage/*therapeutic use;
Central Serous Chorioretinopathy/*drug therapy/pathology;
Choroid/*pathology;
Female;
Humans;
Intravitreal Injections;
Male;
Middle Aged;
Retrospective Studies;
Treatment Outcome
- From:Korean Journal of Ophthalmology
2015;29(3):160-167
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To analyze differences in the subfoveal choroidal thickness (SFChT) between bevacizumab responders (BevRs) and nonresponders (BevNRs) in patients with idiopathic central serous chorioretinopathy (CSC). METHODS: The medical records of 30 unilateral chronic CSC patients who were treated with intravitreal bevacizumab (IVB) as a first line treatment were reviewed. Patients were categorized as BevNRs when CSC did not completely resolve after a minimum of 3 IVB treatments. Enhanced depth imaging-optical coherence tomography was used and SFChT was measured before and after treatment. Choroidal hyperpermeability was also evaluated using indocyanine angiography. RESULTS: Twenty and 10 eyes were classified as BevRs or BevNRs, respectively. The mean number of IVB treatments was 2.22 +/- 0.89 in BevRs, and 4.80 +/- 1.03 in BevNRs. Compared with BevNRs, BevRs demonstrated significantly greater pretreatment SFChT (441.25 +/- 88.09 vs. 364.10 +/- 61.97 microm); SFChT reduction following IVB was significantly greater in BevRs than BevNRs. SFChT in the unaffected eyes was also greater in BevRs than BevNRs. Choroidal hyperpermeability was detected less frequently in BevNRs (hypofluorescence on late-phase, 0.0% and 33.3% in BevNRs and BevRs, respectively; p = 0.049). CONCLUSIONS: Compared with CSC eyes that did not respond well to IVB, BevRs demonstrated significantly thicker SFChT at baseline, greater reduction in SFChT after IVB treatment, and hyperfluorescence on late-phase indocyanine green angiography. We recommend IVB injection as the first-line therapy for CSC eyes with relatively high SFChT and hyperfluorescence on late-phase indocyanine green angiography.
